Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: The REACH protocol

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Habl, Gregor ^a   Jensen, Alexandra D ^a   Potthoff, Karin ^a   Uhl, Matthias ^a   Hof, Holger ^a   Hajda, Jacek ^a   Simon, Christian ^a   Debus, Jürgen ^a   Krempien, Robert ^b   Münter, Marc W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; FLUOROURACIL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CONTROL; CANCER SURVIVAL; DISEASE FREE SURVIVAL; GENOMICS; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; INTENSITY MODULATED RADIATION THERAPY; LARYNX CARCINOMA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEOMICS; SQUAMOUS CELL CARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CLINICAL TRIAL; GERMANY; HEAD AND NECK TUMOR; HYPOPHARYNX TUMOR; KAPLAN MEIER METHOD; LARYNX TUMOR; MORTALITY; MULTICENTER STUDY; OROPHARYNX TUMOR; PATHOLOGY; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FLUOROURACIL; GERMANY; HUMANS; HYPOPHARYNGEAL NEOPLASMS; KAPLAN-MEIER ESTIMATE; LARYNGEAL NEOPLASMS; OROPHARYNGEAL NEOPLASMS; OTORHINOLARYNGOLOGIC NEOPLASMS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, INTENSITY-MODULATED; TIME FACTORS; TREATMENT OUTCOME;

EID: 78649316780     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-651     Document Type: Article

References (22)

1. Pignon JP, le Maitre A, Maillard E, Bourhis J, . MACH-NC Collaborative Group Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiotherapy and Oncology 2009, 92:4-14. 10.1016/j.radonc.2009.04.014, 19446902, MACH-NC Collaborative Group.
2. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006, 6:28. 10.1186/1471-2407-6-28, 1379652, 16448551.
3. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006, 368(9538):843-854. 10.1016/S0140-6736(06)69121-6, 16950362.
4. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001, 50(5):1161-1171. 10.1016/S0360-3016(01)01544-9, 11483325.
5. Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006, 17(3):450-456. 10.1093/annonc/mdj084, 16303861.
6. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19(3):183-232. 10.1016/1040-8428(94)00144-I, 7612182.
7. Wilke H, Glynne-Jones R, Thaler J, . MABEL - A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. J Clin Oncol 2006, 24(18S):Abstract 3549.
8. Baselga J. The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer 2001, 37(Suppl 4):S16-S22. 10.1016/S0959-8049(01)00233-7, 11597400.
9. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993, 53(19):4637-4642.
10. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000, 6(2):701-708.
11. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578. 10.1056/NEJMoa053422, 16467544.
12. Bonner JA, Ang K. More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med 2007, 357:1872-3. author reply 1873, 10.1056/NEJMc076359, 17978301.
13. Erbitux SmPC (Feb 2007). 2007, Ref Type: Report.
14. Siena S, Glynne-Jones R, Thaler J. MABEL - A large mulitnational study of cetuximab plus irinotecan in irinotecan-resistant metastatic colorectal cancer: Update on infusion related reactions (IRR). ASCO Gastrointestinal Cancer Symposium 2007, Abstract 353.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
16. Garcia-Huttenlocher HI, Timke C, Dinkel J, Huber PE, Debus J, Muenter MW. Acute Toxicity of Skin and Mucosa in Patients with Head and Neck Cancer Receiving Radiotherapy Alone or in Combination with Chemotherapy or Cetuximab. Proceedings of the 5th Annual ASTRO Meeting
17. Budach W, Bölke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007, 357:514-5. 10.1056/NEJMc071075, 17671265.
18. Giro C, Berger B, Bölke E, Ciernuk IF, Duprez F, Locati L, Maillard S, Ozsahin M, Pfeffer R, Robertson G, Langendijk JA, Budach W. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes. Radiotherapy and Oncology 2009, 90:166-171. 10.1016/j.radonc.2008.09.007, 18977050.
19. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clin Adv Hematol Oncol 2007, 5(2):79-81.
20. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006, 24(7):1072-1078. 10.1200/JCO.2004.00.1792, 16505426.
21. Nutting C, A'Hern R, Rogers MS, Sydenham MA, Adab F, Harrington K, Jefferies S, Scrase C, Yap BK, Hall E. First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer. 2009 ASCO Annual Meeting, Abstract No: LBA6006, Citation: J Clin Oncol 2009, 27:18s. (suppl; abstr LBA6006).
22. Clavel S, Nguyen D, Després P, Fortin B, Coulombe G, Donath D, Soulières D, Charpentier D, Guertin L, F P. Nguyen-Tan: Higher dose per fraction and shorter overall treatment time using intensity-modulated radiation therapy versus conventional radiation therapy with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma: A comparison of toxicity and efficacy. 2009 ASCO Annual Meeting, Abstract No: 6038, Citation: J Clin Oncol 2009, 27:15s. (suppl; abstr 6038).